The Kirby Institute’s infectious disease research collaboration with the University of Medicine 2 (UM2) in Yangon, Myanmar, continues to make strides in building research capacity in Myanmar.
In November 2017, the US Clinical Practice Guidelines in Oncology were updated to list pomalidomide, an oral immune regulator, as the preferred regimen for relapsed Kaposi’s sarcoma (KS), based on a U.S.
The Kirby Institute will be closed over the Christmas/New Year break. Our last day of operations is Tuesday 19 December 2017 and we reopen Tuesday 2 January 2018.
From all of us, we wish you a safe and happy festive season and we look forward to what's to come in 2018!
The Kirby Institute at UNSW Sydney has received $9,060,140 for a Program Grant to conduct research on improving the lives of people with problematic drug use.
The Kirby Institute's Dr Angela Kelly-Hanku, from the Public Health Interventions Research Group, has been appointed a Scientia Fellowship by UNSW.
We would like to congratulate our colleague, Dr Muhammad Jamil, on being one of two recipients of the 2017 Dean of Medicine’s Award for Outstanding Contribution to Research by a Higher Degree Research Student.
Federal Health Minister Greg Hunt has visited the Kirby Institute at UNSW Sydney to announce a $70 million funding boost to build the capacity of Australia’s next generation of medical researchers.
On Thursday 24 November, the Kirby Institute held its 6th Brett Tindall Memorial Lecture, our annual lecture awarded to a world leader in infectious disease research.
Australia’s world-first human papillomavirus (HPV) vaccination program will dramatically reduce the incidence of cancer of the cervix for several decades, according to new research published in the Journal of Infectious Diseases.